nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—prostate cancer	0.343	1	CbGaD
Clodronate—SLC25A6—prostate gland—prostate cancer	0.0122	0.091	CbGeAlD
Clodronate—SLC25A5—prostate gland—prostate cancer	0.0106	0.0791	CbGeAlD
Clodronate—SLC25A4—prostate gland—prostate cancer	0.00997	0.0742	CbGeAlD
Clodronate—SLC25A5—seminal vesicle—prostate cancer	0.009	0.0669	CbGeAlD
Clodronate—SLC25A6—epithelium—prostate cancer	0.00899	0.0668	CbGeAlD
Clodronate—SLC25A6—renal system—prostate cancer	0.00834	0.062	CbGeAlD
Clodronate—SLC25A5—epithelium—prostate cancer	0.00782	0.0582	CbGeAlD
Clodronate—SLC25A5—renal system—prostate cancer	0.00725	0.0539	CbGeAlD
Clodronate—SLC25A5—urethra—prostate cancer	0.00712	0.053	CbGeAlD
Clodronate—SLC25A4—renal system—prostate cancer	0.0068	0.0505	CbGeAlD
Clodronate—SLC25A6—bone marrow—prostate cancer	0.0063	0.0469	CbGeAlD
Clodronate—SLC25A5—bone marrow—prostate cancer	0.00548	0.0408	CbGeAlD
Clodronate—SLC25A6—testis—prostate cancer	0.00539	0.0401	CbGeAlD
Clodronate—SLC25A5—testis—prostate cancer	0.00469	0.0349	CbGeAlD
Clodronate—SLC25A4—testis—prostate cancer	0.00439	0.0327	CbGeAlD
Clodronate—SLC25A6—lymph node—prostate cancer	0.00391	0.029	CbGeAlD
Clodronate—SLC25A5—lymph node—prostate cancer	0.0034	0.0253	CbGeAlD
Clodronate—SLC25A4—lymph node—prostate cancer	0.00318	0.0237	CbGeAlD
Clodronate—PTGS2—prostate gland—prostate cancer	0.002	0.0149	CbGeAlD
Clodronate—PTGS2—seminal vesicle—prostate cancer	0.00169	0.0126	CbGeAlD
Clodronate—PTGS2—epithelium—prostate cancer	0.00147	0.011	CbGeAlD
Clodronate—PTGS2—renal system—prostate cancer	0.00137	0.0102	CbGeAlD
Clodronate—PTGS2—urethra—prostate cancer	0.00134	0.00998	CbGeAlD
Clodronate—PTGS2—bone marrow—prostate cancer	0.00103	0.00768	CbGeAlD
Clodronate—PTGS2—lymph node—prostate cancer	0.00064	0.00476	CbGeAlD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000387	0.00134	CcSEcCtD
Clodronate—Pharyngitis—Mitoxantrone—prostate cancer	0.000385	0.00133	CcSEcCtD
Clodronate—Cardiac failure—Capecitabine—prostate cancer	0.000385	0.00133	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000383	0.00132	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—prostate cancer	0.000382	0.00132	CcSEcCtD
Clodronate—Pruritus—Bicalutamide—prostate cancer	0.00038	0.00131	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—prostate cancer	0.000379	0.00131	CcSEcCtD
Clodronate—Mediastinal disorder—Estradiol—prostate cancer	0.000376	0.0013	CcSEcCtD
Clodronate—Nausea—Cabazitaxel—prostate cancer	0.000372	0.00128	CcSEcCtD
Clodronate—Infection—Goserelin—prostate cancer	0.000371	0.00128	CcSEcCtD
Clodronate—Infection—Conjugated Estrogens—prostate cancer	0.000368	0.00127	CcSEcCtD
Clodronate—Diarrhoea—Bicalutamide—prostate cancer	0.000367	0.00127	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—prostate cancer	0.000364	0.00126	CcSEcCtD
Clodronate—Skin disorder—Goserelin—prostate cancer	0.000363	0.00125	CcSEcCtD
Clodronate—Oliguria—Doxorubicin—prostate cancer	0.000362	0.00125	CcSEcCtD
Clodronate—Pneumonia—Etoposide—prostate cancer	0.000362	0.00125	CcSEcCtD
Clodronate—Dehydration—Docetaxel—prostate cancer	0.000361	0.00125	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—prostate cancer	0.000361	0.00124	CcSEcCtD
Clodronate—Urticaria—Ethinyl Estradiol—prostate cancer	0.000361	0.00124	CcSEcCtD
Clodronate—Skin disorder—Conjugated Estrogens—prostate cancer	0.000359	0.00124	CcSEcCtD
Clodronate—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000359	0.00124	CcSEcCtD
Clodronate—Anorexia—Goserelin—prostate cancer	0.000356	0.00123	CcSEcCtD
Clodronate—Abdominal pain upper—Docetaxel—prostate cancer	0.000354	0.00122	CcSEcCtD
Clodronate—Renal failure—Etoposide—prostate cancer	0.000354	0.00122	CcSEcCtD
Clodronate—Anorexia—Conjugated Estrogens—prostate cancer	0.000353	0.00122	CcSEcCtD
Clodronate—Blood creatinine increased—Capecitabine—prostate cancer	0.000352	0.00121	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—prostate cancer	0.000351	0.00121	CcSEcCtD
Clodronate—Dehydration—Capecitabine—prostate cancer	0.000349	0.00121	CcSEcCtD
Clodronate—Abdominal pain upper—Capecitabine—prostate cancer	0.000343	0.00118	CcSEcCtD
Clodronate—Cardiac failure—Prednisone—prostate cancer	0.000343	0.00118	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.000342	0.00118	CcSEcCtD
Clodronate—Vomiting—Bicalutamide—prostate cancer	0.000341	0.00118	CcSEcCtD
Clodronate—Rash—Bicalutamide—prostate cancer	0.000339	0.00117	CcSEcCtD
Clodronate—Dermatitis—Bicalutamide—prostate cancer	0.000338	0.00117	CcSEcCtD
Clodronate—Dysphagia—Docetaxel—prostate cancer	0.000335	0.00116	CcSEcCtD
Clodronate—Hepatocellular injury—Doxorubicin—prostate cancer	0.000334	0.00115	CcSEcCtD
Clodronate—Dyspnoea—Goserelin—prostate cancer	0.000333	0.00115	CcSEcCtD
Clodronate—Angioedema—Estradiol—prostate cancer	0.000332	0.00114	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.000331	0.00114	CcSEcCtD
Clodronate—Bronchospasm—Docetaxel—prostate cancer	0.00033	0.00114	CcSEcCtD
Clodronate—Dyspnoea—Conjugated Estrogens—prostate cancer	0.00033	0.00114	CcSEcCtD
Clodronate—Dyspepsia—Goserelin—prostate cancer	0.000329	0.00113	CcSEcCtD
Clodronate—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000326	0.00112	CcSEcCtD
Clodronate—Dysphagia—Capecitabine—prostate cancer	0.000325	0.00112	CcSEcCtD
Clodronate—Decreased appetite—Goserelin—prostate cancer	0.000325	0.00112	CcSEcCtD
Clodronate—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000322	0.00111	CcSEcCtD
Clodronate—Pruritus—Ethinyl Estradiol—prostate cancer	0.000321	0.00111	CcSEcCtD
Clodronate—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000319	0.0011	CcSEcCtD
Clodronate—Bronchospasm—Capecitabine—prostate cancer	0.000319	0.0011	CcSEcCtD
Clodronate—Urinary tract disorder—Etoposide—prostate cancer	0.000319	0.0011	CcSEcCtD
Clodronate—Nausea—Bicalutamide—prostate cancer	0.000319	0.0011	CcSEcCtD
Clodronate—Urethral disorder—Etoposide—prostate cancer	0.000317	0.00109	CcSEcCtD
Clodronate—Anaemia—Mitoxantrone—prostate cancer	0.000312	0.00108	CcSEcCtD
Clodronate—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000311	0.00107	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000307	0.00106	CcSEcCtD
Clodronate—Pneumonia—Docetaxel—prostate cancer	0.000301	0.00104	CcSEcCtD
Clodronate—Hepatic function abnormal—Epirubicin—prostate cancer	0.0003	0.00103	CcSEcCtD
Clodronate—Urticaria—Goserelin—prostate cancer	0.000297	0.00102	CcSEcCtD
Clodronate—Abdominal pain—Goserelin—prostate cancer	0.000295	0.00102	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Prednisone—prostate cancer	0.000295	0.00102	CcSEcCtD
Clodronate—Infection—Estradiol—prostate cancer	0.000294	0.00102	CcSEcCtD
Clodronate—Renal failure—Docetaxel—prostate cancer	0.000294	0.00101	CcSEcCtD
Clodronate—Urticaria—Conjugated Estrogens—prostate cancer	0.000294	0.00101	CcSEcCtD
Clodronate—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000293	0.00101	CcSEcCtD
Clodronate—Pneumonia—Capecitabine—prostate cancer	0.000291	0.001	CcSEcCtD
Clodronate—Mediastinal disorder—Etoposide—prostate cancer	0.000291	0.001	CcSEcCtD
Clodronate—Vomiting—Ethinyl Estradiol—prostate cancer	0.000289	0.000996	CcSEcCtD
Clodronate—Skin disorder—Estradiol—prostate cancer	0.000288	0.000992	CcSEcCtD
Clodronate—Rash—Ethinyl Estradiol—prostate cancer	0.000286	0.000987	CcSEcCtD
Clodronate—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000286	0.000986	CcSEcCtD
Clodronate—Renal failure—Capecitabine—prostate cancer	0.000285	0.000982	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—prostate cancer	0.000284	0.000978	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000277	0.000956	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—prostate cancer	0.000275	0.000949	CcSEcCtD
Clodronate—Infection—Mitoxantrone—prostate cancer	0.000274	0.000946	CcSEcCtD
Clodronate—Nausea—Ethinyl Estradiol—prostate cancer	0.00027	0.00093	CcSEcCtD
Clodronate—Cardiac failure—Epirubicin—prostate cancer	0.000268	0.000925	CcSEcCtD
Clodronate—Skin disorder—Mitoxantrone—prostate cancer	0.000268	0.000925	CcSEcCtD
Clodronate—Pharyngitis—Docetaxel—prostate cancer	0.000266	0.000919	CcSEcCtD
Clodronate—Urinary tract disorder—Docetaxel—prostate cancer	0.000265	0.000915	CcSEcCtD
Clodronate—Pruritus—Goserelin—prostate cancer	0.000264	0.000912	CcSEcCtD
Clodronate—Dyspnoea—Estradiol—prostate cancer	0.000264	0.000911	CcSEcCtD
Clodronate—Connective tissue disorder—Docetaxel—prostate cancer	0.000264	0.00091	CcSEcCtD
Clodronate—Urethral disorder—Docetaxel—prostate cancer	0.000263	0.000908	CcSEcCtD
Clodronate—Anorexia—Mitoxantrone—prostate cancer	0.000263	0.000907	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—prostate cancer	0.000262	0.000905	CcSEcCtD
Clodronate—Pruritus—Conjugated Estrogens—prostate cancer	0.000262	0.000903	CcSEcCtD
Clodronate—Dyspepsia—Estradiol—prostate cancer	0.000261	0.000899	CcSEcCtD
Clodronate—Anaemia—Etoposide—prostate cancer	0.00026	0.000897	CcSEcCtD
Clodronate—Pharyngitis—Capecitabine—prostate cancer	0.000258	0.00089	CcSEcCtD
Clodronate—Decreased appetite—Estradiol—prostate cancer	0.000257	0.000888	CcSEcCtD
Clodronate—Urinary tract disorder—Capecitabine—prostate cancer	0.000257	0.000886	CcSEcCtD
Clodronate—Gastrointestinal disorder—Estradiol—prostate cancer	0.000256	0.000882	CcSEcCtD
Clodronate—Diarrhoea—Goserelin—prostate cancer	0.000256	0.000882	CcSEcCtD
Clodronate—Connective tissue disorder—Capecitabine—prostate cancer	0.000255	0.000881	CcSEcCtD
Clodronate—Urethral disorder—Capecitabine—prostate cancer	0.000255	0.000879	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—prostate cancer	0.000254	0.000878	CcSEcCtD
Clodronate—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000253	0.000873	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—prostate cancer	0.000248	0.000856	CcSEcCtD
Clodronate—Dyspnoea—Mitoxantrone—prostate cancer	0.000246	0.000849	CcSEcCtD
Clodronate—Blood creatinine increased—Epirubicin—prostate cancer	0.000245	0.000846	CcSEcCtD
Clodronate—Dehydration—Epirubicin—prostate cancer	0.000243	0.00084	CcSEcCtD
Clodronate—Dyspepsia—Mitoxantrone—prostate cancer	0.000243	0.000838	CcSEcCtD
Clodronate—Mediastinal disorder—Docetaxel—prostate cancer	0.000242	0.000835	CcSEcCtD
Clodronate—Decreased appetite—Mitoxantrone—prostate cancer	0.00024	0.000828	CcSEcCtD
Clodronate—Abdominal pain upper—Epirubicin—prostate cancer	0.000239	0.000825	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000238	0.00082	CcSEcCtD
Clodronate—Vomiting—Goserelin—prostate cancer	0.000238	0.000819	CcSEcCtD
Clodronate—Rash—Goserelin—prostate cancer	0.000236	0.000813	CcSEcCtD
Clodronate—Dermatitis—Goserelin—prostate cancer	0.000235	0.000812	CcSEcCtD
Clodronate—Vomiting—Conjugated Estrogens—prostate cancer	0.000235	0.000812	CcSEcCtD
Clodronate—Urticaria—Estradiol—prostate cancer	0.000235	0.000812	CcSEcCtD
Clodronate—Mediastinal disorder—Capecitabine—prostate cancer	0.000234	0.000808	CcSEcCtD
Clodronate—Abdominal pain—Estradiol—prostate cancer	0.000234	0.000808	CcSEcCtD
Clodronate—Rash—Conjugated Estrogens—prostate cancer	0.000233	0.000805	CcSEcCtD
Clodronate—Dermatitis—Conjugated Estrogens—prostate cancer	0.000233	0.000804	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000231	0.000797	CcSEcCtD
Clodronate—Infection—Etoposide—prostate cancer	0.000228	0.000787	CcSEcCtD
Clodronate—Connective tissue disorder—Prednisone—prostate cancer	0.000228	0.000785	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—prostate cancer	0.000227	0.000783	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—prostate cancer	0.000226	0.000781	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—prostate cancer	0.000225	0.000777	CcSEcCtD
Clodronate—Skin disorder—Etoposide—prostate cancer	0.000223	0.000769	CcSEcCtD
Clodronate—Nausea—Goserelin—prostate cancer	0.000222	0.000766	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—prostate cancer	0.000221	0.000763	CcSEcCtD
Clodronate—Nausea—Conjugated Estrogens—prostate cancer	0.00022	0.000758	CcSEcCtD
Clodronate—Urticaria—Mitoxantrone—prostate cancer	0.000219	0.000756	CcSEcCtD
Clodronate—Anorexia—Etoposide—prostate cancer	0.000219	0.000755	CcSEcCtD
Clodronate—Abdominal pain—Mitoxantrone—prostate cancer	0.000218	0.000753	CcSEcCtD
Clodronate—Anaemia—Docetaxel—prostate cancer	0.000216	0.000745	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000214	0.000737	CcSEcCtD
Clodronate—Pruritus—Estradiol—prostate cancer	0.00021	0.000723	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—prostate cancer	0.000209	0.000722	CcSEcCtD
Clodronate—Anaemia—Capecitabine—prostate cancer	0.000209	0.000722	CcSEcCtD
Clodronate—Dyspnoea—Etoposide—prostate cancer	0.000205	0.000706	CcSEcCtD
Clodronate—Pneumonia—Epirubicin—prostate cancer	0.000203	0.0007	CcSEcCtD
Clodronate—Diarrhoea—Estradiol—prostate cancer	0.000203	0.000699	CcSEcCtD
Clodronate—Decreased appetite—Etoposide—prostate cancer	0.0002	0.000688	CcSEcCtD
Clodronate—Renal failure—Epirubicin—prostate cancer	0.000198	0.000684	CcSEcCtD
Clodronate—Gastrointestinal disorder—Etoposide—prostate cancer	0.000198	0.000684	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000198	0.000682	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000191	0.00066	CcSEcCtD
Clodronate—Infection—Docetaxel—prostate cancer	0.000189	0.000654	CcSEcCtD
Clodronate—Diarrhoea—Mitoxantrone—prostate cancer	0.000189	0.000651	CcSEcCtD
Clodronate—Vomiting—Estradiol—prostate cancer	0.000188	0.00065	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—prostate cancer	0.000188	0.000648	CcSEcCtD
Clodronate—Rash—Estradiol—prostate cancer	0.000187	0.000644	CcSEcCtD
Clodronate—Dermatitis—Estradiol—prostate cancer	0.000187	0.000644	CcSEcCtD
Clodronate—Anaemia—Prednisone—prostate cancer	0.000186	0.000643	CcSEcCtD
Clodronate—Skin disorder—Docetaxel—prostate cancer	0.000185	0.000639	CcSEcCtD
Clodronate—Angioedema—Prednisone—prostate cancer	0.000184	0.000635	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—prostate cancer	0.000183	0.000633	CcSEcCtD
Clodronate—Infection—Capecitabine—prostate cancer	0.000183	0.000633	CcSEcCtD
Clodronate—Urticaria—Etoposide—prostate cancer	0.000182	0.000629	CcSEcCtD
Clodronate—Anorexia—Docetaxel—prostate cancer	0.000182	0.000627	CcSEcCtD
Clodronate—Abdominal pain—Etoposide—prostate cancer	0.000181	0.000626	CcSEcCtD
Clodronate—Pharyngitis—Epirubicin—prostate cancer	0.00018	0.00062	CcSEcCtD
Clodronate—Skin disorder—Capecitabine—prostate cancer	0.000179	0.000619	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—prostate cancer	0.000179	0.000617	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—prostate cancer	0.000178	0.000614	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—prostate cancer	0.000178	0.000612	CcSEcCtD
Clodronate—Anorexia—Capecitabine—prostate cancer	0.000176	0.000607	CcSEcCtD
Clodronate—Nausea—Estradiol—prostate cancer	0.000176	0.000607	CcSEcCtD
Clodronate—Vomiting—Mitoxantrone—prostate cancer	0.000175	0.000605	CcSEcCtD
Clodronate—Rash—Mitoxantrone—prostate cancer	0.000174	0.0006	CcSEcCtD
Clodronate—Dermatitis—Mitoxantrone—prostate cancer	0.000174	0.0006	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.00017	0.000588	CcSEcCtD
Clodronate—Dyspnoea—Docetaxel—prostate cancer	0.00017	0.000587	CcSEcCtD
Clodronate—Dyspepsia—Docetaxel—prostate cancer	0.000168	0.000579	CcSEcCtD
Clodronate—Pharyngitis—Doxorubicin—prostate cancer	0.000166	0.000574	CcSEcCtD
Clodronate—Decreased appetite—Docetaxel—prostate cancer	0.000166	0.000572	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—prostate cancer	0.000165	0.000571	CcSEcCtD
Clodronate—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000165	0.000568	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—prostate cancer	0.000165	0.000568	CcSEcCtD
Clodronate—Dyspnoea—Capecitabine—prostate cancer	0.000165	0.000568	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—prostate cancer	0.000164	0.000567	CcSEcCtD
Clodronate—Nausea—Mitoxantrone—prostate cancer	0.000164	0.000565	CcSEcCtD
Clodronate—Infection—Prednisone—prostate cancer	0.000163	0.000564	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—prostate cancer	0.000163	0.000563	CcSEcCtD
Clodronate—Dyspepsia—Capecitabine—prostate cancer	0.000163	0.000561	CcSEcCtD
Clodronate—Pruritus—Etoposide—prostate cancer	0.000162	0.00056	CcSEcCtD
Clodronate—Decreased appetite—Capecitabine—prostate cancer	0.000161	0.000554	CcSEcCtD
Clodronate—Skin disorder—Prednisone—prostate cancer	0.00016	0.000551	CcSEcCtD
Clodronate—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000159	0.00055	CcSEcCtD
Clodronate—Diarrhoea—Etoposide—prostate cancer	0.000157	0.000542	CcSEcCtD
Clodronate—Anorexia—Prednisone—prostate cancer	0.000157	0.000541	CcSEcCtD
Clodronate—Mediastinal disorder—Doxorubicin—prostate cancer	0.000151	0.000521	CcSEcCtD
Clodronate—Abdominal pain—Docetaxel—prostate cancer	0.000151	0.00052	CcSEcCtD
Clodronate—Urticaria—Capecitabine—prostate cancer	0.000147	0.000506	CcSEcCtD
Clodronate—Abdominal pain—Capecitabine—prostate cancer	0.000146	0.000504	CcSEcCtD
Clodronate—Vomiting—Etoposide—prostate cancer	0.000146	0.000503	CcSEcCtD
Clodronate—Anaemia—Epirubicin—prostate cancer	0.000146	0.000503	CcSEcCtD
Clodronate—Dyspepsia—Prednisone—prostate cancer	0.000145	0.0005	CcSEcCtD
Clodronate—Rash—Etoposide—prostate cancer	0.000145	0.000499	CcSEcCtD
Clodronate—Dermatitis—Etoposide—prostate cancer	0.000145	0.000499	CcSEcCtD
Clodronate—Decreased appetite—Prednisone—prostate cancer	0.000143	0.000493	CcSEcCtD
Clodronate—Nausea—Etoposide—prostate cancer	0.000136	0.00047	CcSEcCtD
Clodronate—Pruritus—Docetaxel—prostate cancer	0.000135	0.000466	CcSEcCtD
Clodronate—Anaemia—Doxorubicin—prostate cancer	0.000135	0.000465	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000133	0.00046	CcSEcCtD
Clodronate—Urticaria—Prednisone—prostate cancer	0.000131	0.000451	CcSEcCtD
Clodronate—Pruritus—Capecitabine—prostate cancer	0.000131	0.000451	CcSEcCtD
Clodronate—Diarrhoea—Docetaxel—prostate cancer	0.000131	0.00045	CcSEcCtD
Clodronate—Abdominal pain—Prednisone—prostate cancer	0.00013	0.000449	CcSEcCtD
Clodronate—Infection—Epirubicin—prostate cancer	0.000128	0.000441	CcSEcCtD
Clodronate—Diarrhoea—Capecitabine—prostate cancer	0.000126	0.000436	CcSEcCtD
Clodronate—Skin disorder—Epirubicin—prostate cancer	0.000125	0.000431	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000123	0.000425	CcSEcCtD
Clodronate—Anorexia—Epirubicin—prostate cancer	0.000123	0.000423	CcSEcCtD
Clodronate—Vomiting—Docetaxel—prostate cancer	0.000121	0.000418	CcSEcCtD
Clodronate—Rash—Docetaxel—prostate cancer	0.00012	0.000415	CcSEcCtD
Clodronate—Dermatitis—Docetaxel—prostate cancer	0.00012	0.000415	CcSEcCtD
Clodronate—Infection—Doxorubicin—prostate cancer	0.000118	0.000408	CcSEcCtD
Clodronate—Vomiting—Capecitabine—prostate cancer	0.000117	0.000405	CcSEcCtD
Clodronate—Rash—Capecitabine—prostate cancer	0.000116	0.000402	CcSEcCtD
Clodronate—Pruritus—Prednisone—prostate cancer	0.000116	0.000402	CcSEcCtD
Clodronate—Dermatitis—Capecitabine—prostate cancer	0.000116	0.000401	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—prostate cancer	0.000116	0.000399	CcSEcCtD
Clodronate—Dyspnoea—Epirubicin—prostate cancer	0.000115	0.000396	CcSEcCtD
Clodronate—Anorexia—Doxorubicin—prostate cancer	0.000113	0.000391	CcSEcCtD
Clodronate—Nausea—Docetaxel—prostate cancer	0.000113	0.000391	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—prostate cancer	0.000113	0.000391	CcSEcCtD
Clodronate—Diarrhoea—Prednisone—prostate cancer	0.000113	0.000388	CcSEcCtD
Clodronate—Decreased appetite—Epirubicin—prostate cancer	0.000112	0.000386	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000111	0.000383	CcSEcCtD
Clodronate—Nausea—Capecitabine—prostate cancer	0.00011	0.000378	CcSEcCtD
Clodronate—Dyspnoea—Doxorubicin—prostate cancer	0.000106	0.000366	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—prostate cancer	0.000105	0.000362	CcSEcCtD
Clodronate—Vomiting—Prednisone—prostate cancer	0.000105	0.000361	CcSEcCtD
Clodronate—Rash—Prednisone—prostate cancer	0.000104	0.000358	CcSEcCtD
Clodronate—Dermatitis—Prednisone—prostate cancer	0.000104	0.000358	CcSEcCtD
Clodronate—Decreased appetite—Doxorubicin—prostate cancer	0.000103	0.000357	CcSEcCtD
Clodronate—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000103	0.000355	CcSEcCtD
Clodronate—Urticaria—Epirubicin—prostate cancer	0.000102	0.000353	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—prostate cancer	0.000102	0.000351	CcSEcCtD
Clodronate—Nausea—Prednisone—prostate cancer	9.77e-05	0.000337	CcSEcCtD
Clodronate—Urticaria—Doxorubicin—prostate cancer	9.46e-05	0.000326	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—prostate cancer	9.41e-05	0.000325	CcSEcCtD
Clodronate—Pruritus—Epirubicin—prostate cancer	9.1e-05	0.000314	CcSEcCtD
Clodronate—Diarrhoea—Epirubicin—prostate cancer	8.8e-05	0.000304	CcSEcCtD
Clodronate—Pruritus—Doxorubicin—prostate cancer	8.42e-05	0.000291	CcSEcCtD
Clodronate—Vomiting—Epirubicin—prostate cancer	8.18e-05	0.000282	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—prostate cancer	8.14e-05	0.000281	CcSEcCtD
Clodronate—Rash—Epirubicin—prostate cancer	8.11e-05	0.00028	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—prostate cancer	8.1e-05	0.00028	CcSEcCtD
Clodronate—Nausea—Epirubicin—prostate cancer	7.64e-05	0.000264	CcSEcCtD
Clodronate—Vomiting—Doxorubicin—prostate cancer	7.57e-05	0.000261	CcSEcCtD
Clodronate—Rash—Doxorubicin—prostate cancer	7.51e-05	0.000259	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—prostate cancer	7.5e-05	0.000259	CcSEcCtD
Clodronate—Nausea—Doxorubicin—prostate cancer	7.07e-05	0.000244	CcSEcCtD
Clodronate—SLC25A6—Metabolism—PIK3CB—prostate cancer	4.17e-05	0.000179	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—prostate cancer	4.14e-05	0.000178	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—prostate cancer	4.14e-05	0.000177	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	4.11e-05	0.000176	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EP300—prostate cancer	4.11e-05	0.000176	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—EP300—prostate cancer	4.1e-05	0.000176	CbGpPWpGaD
Clodronate—SLC25A4—Disease—JAK2—prostate cancer	4.1e-05	0.000176	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	4.09e-05	0.000175	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—INS—prostate cancer	4.03e-05	0.000173	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAP2K1—prostate cancer	4e-05	0.000172	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MDM2—prostate cancer	4e-05	0.000171	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SRC—prostate cancer	3.99e-05	0.000171	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HSD17B1—prostate cancer	3.99e-05	0.000171	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	3.99e-05	0.000171	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—prostate cancer	3.95e-05	0.000169	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CREBBP—prostate cancer	3.94e-05	0.000169	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—prostate cancer	3.94e-05	0.000169	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CB—prostate cancer	3.89e-05	0.000167	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—prostate cancer	3.85e-05	0.000165	CbGpPWpGaD
Clodronate—SLC25A6—Disease—STAT3—prostate cancer	3.85e-05	0.000165	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	3.84e-05	0.000165	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	3.82e-05	0.000164	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—prostate cancer	3.8e-05	0.000163	CbGpPWpGaD
Clodronate—PTGS2—Disease—WNT4—prostate cancer	3.79e-05	0.000162	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	3.78e-05	0.000162	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CD—prostate cancer	3.74e-05	0.00016	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—prostate cancer	3.66e-05	0.000157	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1B—prostate cancer	3.65e-05	0.000157	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TGFB1—prostate cancer	3.65e-05	0.000156	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—prostate cancer	3.63e-05	0.000155	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—prostate cancer	3.61e-05	0.000155	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—prostate cancer	3.61e-05	0.000155	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	3.6e-05	0.000154	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—prostate cancer	3.58e-05	0.000153	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—prostate cancer	3.58e-05	0.000153	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TGFB1—prostate cancer	3.57e-05	0.000153	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—prostate cancer	3.56e-05	0.000153	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—B4GALT4—prostate cancer	3.56e-05	0.000153	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HPGD—prostate cancer	3.56e-05	0.000153	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—NOS3—prostate cancer	3.53e-05	0.000151	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—prostate cancer	3.51e-05	0.000151	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—prostate cancer	3.5e-05	0.00015	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—prostate cancer	3.48e-05	0.000149	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—prostate cancer	3.45e-05	0.000148	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—EP300—prostate cancer	3.44e-05	0.000147	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPL12—prostate cancer	3.4e-05	0.000146	CbGpPWpGaD
Clodronate—PTGS2—Disease—LDHB—prostate cancer	3.4e-05	0.000146	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1A—prostate cancer	3.37e-05	0.000144	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—prostate cancer	3.36e-05	0.000144	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TNFRSF21—prostate cancer	3.34e-05	0.000143	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—prostate cancer	3.31e-05	0.000142	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CB—prostate cancer	3.26e-05	0.00014	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP7B1—prostate cancer	3.25e-05	0.00014	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MTAP—prostate cancer	3.25e-05	0.00014	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	3.25e-05	0.000139	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—prostate cancer	3.23e-05	0.000138	CbGpPWpGaD
Clodronate—PTGS2—Disease—TCN2—prostate cancer	3.22e-05	0.000138	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—prostate cancer	3.21e-05	0.000138	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EP300—prostate cancer	3.21e-05	0.000137	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	3.19e-05	0.000137	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	3.18e-05	0.000136	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SULT1E1—prostate cancer	3.17e-05	0.000136	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SRD5A1—prostate cancer	3.17e-05	0.000136	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SRC—prostate cancer	3.12e-05	0.000134	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	3.1e-05	0.000133	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	3.08e-05	0.000132	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	3.07e-05	0.000132	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—prostate cancer	3.04e-05	0.00013	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—prostate cancer	3.04e-05	0.00013	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	3.03e-05	0.00013	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ACSL4—prostate cancer	3.02e-05	0.00013	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HSD17B3—prostate cancer	3.02e-05	0.00013	CbGpPWpGaD
Clodronate—SLC25A4—Disease—STAT3—prostate cancer	3.01e-05	0.000129	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—prostate cancer	3e-05	0.000129	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	3e-05	0.000129	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	2.99e-05	0.000128	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.99e-05	0.000128	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—prostate cancer	2.96e-05	0.000127	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—UMPS—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PHGDH—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ARG2—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.89e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	2.85e-05	0.000122	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—LDHB—prostate cancer	2.84e-05	0.000122	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—prostate cancer	2.82e-05	0.000121	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—prostate cancer	2.79e-05	0.00012	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP3A5—prostate cancer	2.79e-05	0.00012	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TGFB1—prostate cancer	2.79e-05	0.00012	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	2.78e-05	0.000119	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—prostate cancer	2.75e-05	0.000118	CbGpPWpGaD
Clodronate—PTGS2—Disease—GSTO1—prostate cancer	2.74e-05	0.000117	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—prostate cancer	2.73e-05	0.000117	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	2.7e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PDHA1—prostate cancer	2.7e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTA3—prostate cancer	2.7e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—UCP3—prostate cancer	2.7e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TCN2—prostate cancer	2.7e-05	0.000116	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—prostate cancer	2.69e-05	0.000115	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—EP300—prostate cancer	2.68e-05	0.000115	CbGpPWpGaD
Clodronate—PTGS2—Disease—LRP2—prostate cancer	2.62e-05	0.000113	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—prostate cancer	2.58e-05	0.000111	CbGpPWpGaD
Clodronate—PTGS2—Disease—EIF2AK2—prostate cancer	2.57e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Disease—P4HB—prostate cancer	2.57e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPL10—prostate cancer	2.57e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HSD3B1—prostate cancer	2.57e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC22A3—prostate cancer	2.57e-05	0.00011	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—prostate cancer	2.54e-05	0.000109	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIST1H2BG—prostate cancer	2.53e-05	0.000108	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	2.5e-05	0.000107	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	2.49e-05	0.000107	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—prostate cancer	2.48e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	2.48e-05	0.000106	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—prostate cancer	2.48e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTA4—prostate cancer	2.47e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TBXAS1—prostate cancer	2.47e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Disease—NPPA—prostate cancer	2.44e-05	0.000105	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIST1H4H—prostate cancer	2.44e-05	0.000105	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	2.43e-05	0.000104	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	2.41e-05	0.000103	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTA2—prostate cancer	2.4e-05	0.000103	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ABCG5—prostate cancer	2.37e-05	0.000102	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SULT1A1—prostate cancer	2.37e-05	0.000102	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—prostate cancer	2.37e-05	0.000102	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTA1—prostate cancer	2.32e-05	9.94e-05	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	2.3e-05	9.86e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HSD3B2—prostate cancer	2.29e-05	9.83e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTO1—prostate cancer	2.29e-05	9.83e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NAT2—prostate cancer	2.29e-05	9.83e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	2.2e-05	9.45e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PLCB2—prostate cancer	2.2e-05	9.42e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—LRP2—prostate cancer	2.2e-05	9.42e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP2C18—prostate cancer	2.2e-05	9.42e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—P4HB—prostate cancer	2.16e-05	9.24e-05	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	2.11e-05	9.06e-05	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—prostate cancer	2.1e-05	9.01e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC22A1—prostate cancer	2.1e-05	8.99e-05	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—prostate cancer	2.08e-05	8.91e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—B2M—prostate cancer	2.07e-05	8.9e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFBR1—prostate cancer	2.07e-05	8.9e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	2.07e-05	8.89e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SULT2A1—prostate cancer	2.04e-05	8.76e-05	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	2.04e-05	8.76e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKR1C3—prostate cancer	2.04e-05	8.75e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPS19—prostate cancer	2.04e-05	8.75e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRKACB—prostate cancer	2.03e-05	8.71e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MED12—prostate cancer	2.01e-05	8.62e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GNG5—prostate cancer	1.99e-05	8.55e-05	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—prostate cancer	1.99e-05	8.52e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PPP3CA—prostate cancer	1.98e-05	8.49e-05	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—prostate cancer	1.94e-05	8.31e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NCOA3—prostate cancer	1.92e-05	8.24e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRKCZ—prostate cancer	1.91e-05	8.21e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.89e-05	8.1e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CALR—prostate cancer	1.88e-05	8.07e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGFR4—prostate cancer	1.85e-05	7.93e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PARP1—prostate cancer	1.85e-05	7.93e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HPGDS—prostate cancer	1.83e-05	7.86e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CALCA—prostate cancer	1.83e-05	7.83e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP2C19—prostate cancer	1.82e-05	7.81e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTT1—prostate cancer	1.78e-05	7.62e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ACHE—prostate cancer	1.78e-05	7.62e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP2A6—prostate cancer	1.76e-05	7.53e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—HSPA1A—prostate cancer	1.75e-05	7.51e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.75e-05	7.51e-05	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.72e-05	7.4e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKR1C3—prostate cancer	1.71e-05	7.33e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PRKACB—prostate cancer	1.7e-05	7.29e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP17A1—prostate cancer	1.68e-05	7.22e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CASP9—prostate cancer	1.68e-05	7.2e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.66e-05	7.12e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRKCQ—prostate cancer	1.63e-05	6.98e-05	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—prostate cancer	1.62e-05	6.96e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NCOA2—prostate cancer	1.6e-05	6.88e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGF10—prostate cancer	1.55e-05	6.63e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A5—prostate cancer	1.53e-05	6.56e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP2E1—prostate cancer	1.49e-05	6.41e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NQO1—prostate cancer	1.48e-05	6.33e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFBR2—prostate cancer	1.47e-05	6.31e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TH—prostate cancer	1.46e-05	6.24e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ITPR1—prostate cancer	1.45e-05	6.21e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.45e-05	6.2e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP3A4—prostate cancer	1.44e-05	6.18e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP1B1—prostate cancer	1.42e-05	6.07e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GGT1—prostate cancer	1.37e-05	5.88e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NCOA1—prostate cancer	1.35e-05	5.79e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP19A1—prostate cancer	1.33e-05	5.71e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—LPL—prostate cancer	1.33e-05	5.69e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PDGFRB—prostate cancer	1.32e-05	5.64e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—RXRA—prostate cancer	1.29e-05	5.51e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERCC2—prostate cancer	1.27e-05	5.45e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.25e-05	5.36e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB3—prostate cancer	1.24e-05	5.33e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGFR2—prostate cancer	1.24e-05	5.32e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—COMT—prostate cancer	1.24e-05	5.31e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTP1—prostate cancer	1.23e-05	5.28e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ITPR1—prostate cancer	1.21e-05	5.2e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MTHFR—prostate cancer	1.19e-05	5.12e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.19e-05	5.11e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—TERT—prostate cancer	1.19e-05	5.11e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TYMS—prostate cancer	1.15e-05	4.91e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIF1A—prostate cancer	1.14e-05	4.89e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTM1—prostate cancer	1.13e-05	4.86e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—LPL—prostate cancer	1.11e-05	4.77e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CAV1—prostate cancer	1.1e-05	4.73e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP1A1—prostate cancer	1.07e-05	4.6e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ERCC2—prostate cancer	1.06e-05	4.56e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—BAD—prostate cancer	1.04e-05	4.44e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—APC—prostate cancer	1e-05	4.3e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MTHFR—prostate cancer	1e-05	4.29e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGF—prostate cancer	9.92e-06	4.26e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—IRS1—prostate cancer	9.92e-06	4.26e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARA—prostate cancer	9.82e-06	4.21e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—GSK3B—prostate cancer	9.63e-06	4.13e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—INS—prostate cancer	9.5e-06	4.07e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CREBBP—prostate cancer	9.31e-06	3.99e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CAV1—prostate cancer	9.23e-06	3.96e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAP2K1—prostate cancer	8.88e-06	3.81e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CD—prostate cancer	8.82e-06	3.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.82e-06	3.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—SERPINE1—prostate cancer	8.73e-06	3.74e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGF2—prostate cancer	8.45e-06	3.62e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CG—prostate cancer	8.41e-06	3.61e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—NOS3—prostate cancer	8.33e-06	3.57e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—JAK2—prostate cancer	8.1e-06	3.47e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—INS—prostate cancer	7.96e-06	3.41e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MDM2—prostate cancer	7.91e-06	3.39e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CREBBP—prostate cancer	7.79e-06	3.34e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—prostate cancer	7.79e-06	3.34e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CB—prostate cancer	7.69e-06	3.3e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CD—prostate cancer	7.39e-06	3.17e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1B—prostate cancer	7.22e-06	3.1e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NOS3—prostate cancer	6.98e-06	2.99e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—prostate cancer	6.82e-06	2.92e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1A—prostate cancer	6.66e-06	2.86e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—prostate cancer	6.65e-06	2.85e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CB—prostate cancer	6.44e-06	2.76e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—EP300—prostate cancer	6.34e-06	2.72e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—SRC—prostate cancer	6.16e-06	2.64e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—STAT3—prostate cancer	5.94e-06	2.55e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—prostate cancer	5.57e-06	2.39e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—prostate cancer	5.52e-06	2.37e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFB1—prostate cancer	5.51e-06	2.36e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—prostate cancer	5.4e-06	2.32e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—EP300—prostate cancer	5.31e-06	2.28e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—prostate cancer	5.1e-06	2.19e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—prostate cancer	4.69e-06	2.01e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—prostate cancer	4.15e-06	1.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—prostate cancer	3.93e-06	1.68e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—prostate cancer	3.83e-06	1.64e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—prostate cancer	3.21e-06	1.38e-05	CbGpPWpGaD
